State Research Center Vector began clinical trials on the introduction of the vaccine EpiVacCorona three times. This was announced by the head of the department of zoonotic infections and influenza of the center, Alexander Ryzhikov, reports RIA Novosti.
“Clinical trials of the first – second phase for the introduction of a three-time vaccination of this vaccine are currently underway,” Ryzhikov said, adding that the three-time vaccine administration has already been tested on animals – primates, hamsters and guinea pigs.
According to him, the effect of the increase and duration of immunity has been confirmed, primarily in primates, while the composition of the vaccine does not change.
Earlier, the State Scientific Center for Virology and Biotechnology “Vector” said that the Russian vaccine against COVID-19 “EpiVacCorona” can be called effective against three strains of coronavirus at once. According to the results of an experimental test, the antibodies produced by the drug have neutralizing activity against classical, as well as British and South African strains.
Three vaccines against COVID-19 have been registered in Russia: Sputnik V, EpiVacCorona and CoviVak. EpiVacCorona became the second vaccine to receive registration – it happened on October 14, 2020. About a month later, the developers received permission to conduct post-registration studies, including among the elderly.